SCHEDULE 13G/A: BlackRock Discloses 5.7% Passive Stake in ITEOS THERAPEUTICS INC
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 5.7% beneficial ownership stake in ITEOS THERAPEUTICS INC common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,179,420 shares of ITEOS THERAPEUTICS INC common stock.
- This stake represents 5.7% of the total outstanding common stock of ITEOS THERAPEUTICS INC.
- BlackRock holds sole voting power over 2,144,986 shares and sole dispositive power over 2,179,420 shares.
- The filing is an Amendment No. 5 to Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business for passive investment purposes, not to influence or change control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the issuer, ITEOS THERAPEUTICS INC, beyond confirming institutional interest.
Positives
- The disclosure of a significant 5.7% stake by a major institutional investor like BlackRock may signal institutional interest or inclusion in passive investment vehicles for ITEOS THERAPEUTICS INC.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a standard disclosure by a large institutional investor, BlackRock, indicating a passive ownership stake in ITEOS THERAPEUTICS INC. Such filings are common for asset managers that hold significant positions in publicly traded companies, often as part of diversified portfolios or index-tracking funds, and are not intended to influence corporate control.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor confidence or trading decisions.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 04/23/2025 | Date of signing of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, ITEOS THERAPEUTICS INC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.